/Investor DB

Sofinnova Venture Partners — 2017 Investments

2 investments dated 2017 · listed companies and verified rows first · show all

Pionyr Immunotherapeuticspionyrtx.cominDec 2017SEC filingmedium confidence

HealthtechSan Francisco, US

Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)

Board seatMichael Powell· per SEC Form D · $62M raise · filed Dec 2017

Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova VenturesOrbiMed

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Amplyx Pharmaceuticals

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.